Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer

Avantor (NYSE: AVTR) appointed Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) and Chief Transformation Officer, effective May 1, 2026.

Rhea-AI Summary

Avantor (NYSE: AVTR) appointed Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) and Chief Transformation Officer, effective May 1, 2026. He will lead BMP growth, improve operational performance, and head the Revival Management Office to drive enterprise transformation. Benoit Gourdier will remain through end of 2026 to transition the role.

Positive

• Start date: May 1, 2026 for new EVP and Chief Transformation Officer
• Brings operational experience from Cytiva/Danaher including hardware and integrated solutions
• Will lead the Revival Management Office to drive enterprise transformation
• Planned overlap: current BMP leader stays until end of 2026 to ensure transition

Negative

• Transition period extends through end of 2026, creating temporary leadership overlap
• Potential execution risk while implementing broad transformation initiatives across the enterprise

Argus Apr 24 session

+1.80% close to close Open Argus

Details

News Market Reaction – AVTR

In the Apr 24 session, AVTR gained 1.80%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement introduces a new Executive Vice President for Bioscience & Medtech Products and Ch...

Analysis

This announcement introduces a new Executive Vice President for Bioscience & Medtech Products and Chief Transformation Officer to lead Avantor’s Revival efforts. It follows recent steps such as product portfolio integration and biomanufacturing facility expansion, plus a planned CFO transition with reaffirmed 2026 guidance. Shares around $7.76, near the $7.265 52-week low and below the $11.4 200-day MA, highlight the turnaround backdrop. Investors may watch execution on BMP growth, enterprise-wide transformation, and future financial updates.

Key Figures

Start date: May 1, 2026 Business units led: Five business units Transition period: Until end of 2026 +5 more

Start date

May 1, 2026

Ludovic Brellier joining Avantor in new EVP and CTO roles

Business units led

Five business units

Scope of prior role at Cytiva Hardware Solutions

Transition period

Until end of 2026

Timeline for Benoit Gourdier to remain for transition

Current price

$7.76

Pre-news trading level on announcement day

52-week high

$16.17

Comparison point for current share price

52-week low

$7.265

Lower bound of recent trading range near current levels

Market cap

$5,767,182,056

Equity value prior to leadership announcement

Price vs 52-week high

-52.01%

Drawdown from 52-week high before this news

Historical Context

5 past events · Latest: Apr 21

5 events

1. Apr 21

   Product portfolio update

   24h Move

   +0.3%

   Unification of Masterflex fluid handling portfolio across bioprocess workflows.

2. Apr 13

   Facility expansion

   24h Move

   +3.5%

   Expansion of St. Louis site with new microbial and stability testing.

3. Apr 01

   CFO transition

   24h Move

   -0.9%

   Planned CFO departure with interim CFO appointed and 2026 guidance reaffirmed.

4. Feb 11

   Earnings and turnaround

   24h Move

   -13.6%

   2025 results with sales decline, GAAP net loss, and Revival program outline.

5. Jan 15

   Dividend declaration

   24h Move

   +1.2%

   IVR monthly dividend and leverage/book value update, unrelated to Avantor.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bioprocessing, biopharma

2 terms

bioprocessing medical

"Ludovic is a skilled operator who has a successful track record of growing bioprocessing businesses..."

Bioprocessing is the set of manufacturing steps that use living cells or biological ingredients to make medicines, vaccines, diagnostics, or other biological products. Think of it as an assembly line where living systems, rather than machines, create the final product; variations in scale, consistency and cost directly affect a product’s ability to reach patients and generate revenue. Investors watch bioprocessing for its impact on production risk, regulatory approval and profit margins.

biopharma medical

"services for the biopharma industry. While at Cytiva, Mr. Brellier previously served..."

Biopharma companies discover and develop medicines and treatments derived from biological sources—such as proteins, cells, or genetic material—rather than from purely synthetic chemicals. For investors, biopharma matters because successful products can deliver large, protected revenues but require long, costly development and strict regulatory approval, creating a higher-risk, potentially higher-reward profile; think of them as chefs transforming living ingredients into precision medicines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., April 23, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Ludovic Brellier will join the company as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer on May 1, 2026.

In this role, Mr. Brellier will be responsible for growing the BMP business and improving operational performance. He will also lead the Revival Management Office, driving transformation initiatives across the enterprise.

Mr. Brellier is an accomplished executive with deep operational experience across healthcare and strategic business transformation. He joins Avantor from Danaher, where he was most recently President of Cytiva's Hardware Solutions business, leading five business units responsible for early innovation through manufacturing and commercialization of services for the biopharma industry. While at Cytiva, Mr. Brellier previously served as President of Integrated Solutions & Services and VP Business Operations. He also led the effort to establish Cytiva as a standalone operating company within Danaher as well as the integration of Pall Life Sciences and Cytiva.

"Ludovic is a skilled operator who has a successful track record of growing bioprocessing businesses both organically and inorganically, and our BMP segment is a strong platform that has a lot of potential for growth under his leadership," said Emmanuel Ligner, Avantor's President and CEO. "As we execute Revival across our enterprise, Ludovic's past transformation and integration experience will be critical." Ligner concluded.

Mr. Brellier added, "Avantor's bioprocessing platform has leading product brands with rich legacies and strong customer preference. I look forward to leveraging my manufacturing and commercialization skills to enhance our operations and drive sustainable growth in the business by enabling the product brands to reach their full potential. The successful execution of Revival will be critical to the success of both Avantor's business segments," Brellier concluded.

Benoit Gourdier, current Executive Vice President of Avantor's BMP Segment, will stay with the company until on or before the end of 2026 to ensure a smooth transition.

About Avantor
Avantor^® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Investor Relations Contact
Chris Fidyk
Vice President, Investor Relations
Avantor
Chris.Fidyk@avantorsciences.com

Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-announces-ludovic-brellier-as-executive-vice-president-bioscience--medtech-products-bmp--chief-transformation-officer-302752230.html

SOURCE Avantor and Financial News

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Ludovic Brellier start as Avantor EVP, BMP & Chief Transformation Officer (AVTR)?

He begins the role on May 1, 2026. According to Avantor, he will immediately assume responsibility for growing BMP and leading the Revival Management Office across the enterprise.

What responsibilities will Ludovic Brellier have at Avantor (AVTR)?

He will lead growth for Bioscience & Medtech Products and improve operational performance. According to Avantor, he also will head the Revival Management Office to drive transformation initiatives enterprise-wide.

Where did Avantor's new EVP Ludovic Brellier work before joining AVTR?

He joins from Danaher, where he served as President of Cytiva's Hardware Solutions. According to Avantor, his prior roles included President of Integrated Solutions & Services and VP Business Operations at Cytiva.

Will the current BMP leader remain at Avantor after the appointment of Ludovic Brellier (AVTR)?

Yes; Benoit Gourdier will remain with the company until on or before the end of 2026. According to Avantor, this is to ensure a smooth leadership transition for the BMP segment.

How might Ludovic Brellier's appointment affect Avantor's transformation efforts (AVTR)?

The appointment adds a transformation leader responsible for executing Revival across the company. According to Avantor, his integration and operating experience is expected to support operational improvement and BMP business growth.